ADRX ADARx Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802369 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets38.2%
Debt / equity0.00x
Current ratio21.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $2.22M | — | — | $1.55M | — | — |
| R&D expense | $26.71M | — | — | $19.42M | — | — |
| SG&A expense | $7.68M | — | — | $5.15M | — | — |
| Operating income | -$32.18M | — | — | -$23.01M | — | — |
| Net income | -$28.12M | -$25.76M | -$22.67M | -$17.88M | -$18.09M | -$15.55M |
| EBITDA | -$31.88M | — | — | -$22.71M | — | — |
| EPS (basic) | -1.74 | — | — | -1.85 | — | — |
| EPS (diluted) | -1.74 | — | — | -1.85 | — | — |
| Weighted avg. shares (diluted) | 16.13M | — | — | 9.65M | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $570.61M | — | — | $59.18M | — | — |
| Short-term investments | $330.40M | — | — | — | — | — |
| Current assets | $918.51M | — | — | — | — | — |
| PP&E, net | $4.40M | — | — | — | — | — |
| Total assets | $929.06M | — | — | — | — | — |
| Current liabilities | $43.57M | — | — | — | — | — |
| Total liabilities | $354.66M | — | — | — | — | — |
| Shareholders' equity | $574.40M | -$251.05M | -$225.73M | -$182.92M | -$166.92M | -$150.92M |
| Shares outstanding | 107.26M | — | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | — | — | — | — | — | — |
| Depreciation & amortization | $300,000 | — | — | $300,000 | — | — |
| Stock-based compensation | $1,928 | — | — | $1,441 | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.